Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Haus Bioceuticals Inc. has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are assigned to a distinct examiner and are located within a distinct art unit. This concentration indicates that the company's current prosecution is managed by a single individual in a specific department. The use of a single art unit for these filings suggests a narrow technical focus for the company's active matters, which may simplify the coordination of legal arguments across the portfolio. Practitioners should note that the prosecution experience is centralized, with the assigned examiner having control over all matters.
GALSTER, SAMUEL LEONARD is the busiest examiner for this portfolio, holding 2 busiest examiner pending actions. Since there is a single examiner for the active workload, this individual is responsible for the entirety of the company's current cases. The pending office actions in Biotechnology & Pharmaceuticals define the current active prosecution landscape for Haus Bioceuticals Inc., requiring a consistent strategy to address the requirements of the assigned examiner. Practitioners can leverage this lack of diversification to focus their efforts on a single point of contact at the USPTO. However, this also means that the outcome of both matters is subject to the specific biases or standards of a single examiner and art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GALSTER, SAMUEL LEONARD | 2 | 52.1% | +42.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18684291 | Compositions and Methods for Increasing Bioavailability Using Cyclodextrin Modification | GALSTER, SAMUEL LEONARD | — |
| 18684269 | COMPOSITIONS AND METHODS FOR BIMODAL ANTI-VIRAL COMBINATION THERAPY | GALSTER, SAMUEL LEONARD | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18684291 | Compositions and Methods for Increasing Bioavailability Using Cyclodextrin Modification | GALSTER, SAMUEL LEONARD | — |
| 18684269 | COMPOSITIONS AND METHODS FOR BIMODAL ANTI-VIRAL COMBINATION THERAPY | GALSTER, SAMUEL LEONARD | — |
| Art Unit | Apps |
|---|---|
| 1693 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18684291 | Compositions and Methods for Increasing Bioavailability Using Cyclodextrin Modification | GALSTER, SAMUEL LEONARD | 1693 | §102§103§112 | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18684269 | COMPOSITIONS AND METHODS FOR BIMODAL ANTI-VIRAL COMBINATION THERAPY | GALSTER, SAMUEL LEONARD | 1693 | §101§102§103§112 | Non-Final OA | — | Pending | Feb 16, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHaus Bioceuticals Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Samuel Leonard Galster has the most, with 2 of Haus Bioceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
